Bristol-Myers Squibb Company

Bristol-Myers (NYSE: BMY) Faces Lawsuit for Allegedly Delaying its Cancer Drug

Bristol-Myers Squibb Company (NYSE: BMY) disclosed that it has faced lawsuit of $6.4 billion for purportedly delaying its Breyanzi cancer drug to dodge payments to shareholders of the former Celgene Corp, which the drugmaker purchased in 2019.

$BMY

Bristol-Myers (NYSE: BMY) Finalizes Accquisition Of MyoKardia

Bristol-Myers Squibb Company (NYSE: BMY) is now fully own MyoKardia after it has finalized the buying process. BMY has bought MyoKardia Inc. in an all-cash deal for nearly $13.1 billion. After this deal, Bristol-Myers will get mavacamten which is the cardiovascular drug used